Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$7.79K$7.79K−80.5% vs Q3 2020 Net Income-$1.52M-$1.52MN/M vs Q3 2020 EPS Diluted-$0.02-$0.02N/M vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$169,406N/M Margins · derivedGross margin60.2%−37.9 pt vs Q3 2020
Operating margin-8886.5%−6518.3 pt vs Q3 2020
Net margin-19559.4%−16885.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 19, 2021 · 50 d after period end